stocktools
Dilution profile // every instrument, one screen, from SEC filings

Immunovant, Inc. (IMVT)

CIK 1764013 · all EDGAR filings →

Overall dilution risk
HIGHworst of 4 computed signals (offering ability)
= the worst band among the computed sub-ratings, no hidden weighting
Offering ability
HIGHS-3ASR on file 2023-11-09
= is there a registration (S-1/S-3 family) on file without a later withdrawal
no structured fee data on the live registrations, so this is a yes/no, not a size
Overhead supply
LOWwarrants = 0% of O/S
= warrant shares outstanding divided by current shares outstanding (bands: 20% / 50%)
warrants only; converts, ATMs and equity lines are not in free structured data, so the true overhead is AT LEAST this
Historical dilution
MEDIUM+58% O/S in 3y
= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative
Cash need
MEDIUM~23.5 months of runway
= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

2020-11-122026-08-03

Latest: 206.6M shares as of Aug 3, 2026 (10-Q).

Cash runway

Funded — but tight

~24 months of cash · watch

Full breakdown: cash runway tool · source filing →

Warrants

Warrants outstanding: 0 underlying shares, as reported Dec 31, 2020 (10-Q).

Reported exercise price: $11.5 (aggregate figure as tagged; individual tranches vary).

Rough fully diluted estimate: 206.6M = 206.6M O/S + 0 warrant shares. An estimate, not a filing figure: it ignores converts, options and RSUs, and the two inputs carry different as-of dates.

Convertible notes

No convertible-note facts tagged in the 10-Q filed Aug 6, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Registrations and offerings

S-3ASRNov 9, 2023no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 1 executed · 0 registered.

EXECUTEDDec 12, 2025Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5 →
MARKETINGDec 11, 2025Free-writing prospectus — offering being marketedFWP →
UPDATEJan 24, 2025Prospectus update — often a resale registration, not necessarily new capital424B3 →
EXECUTEDJan 13, 2025Unregistered share sale disclosed (8-K item 3.02)8-K →
REGISTEREDNov 9, 2023Automatic shelf registration — effective immediately (large filers)S-3ASR →
EXECUTEDSep 29, 2023Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5 →
MARKETINGSep 28, 2023Free-writing prospectus — offering being marketedFWP →
EXECUTEDSep 28, 2023Unregistered share sale disclosed (8-K item 3.02)8-K →
MARKETINGSep 27, 2023Free-writing prospectus — offering being marketedFWP →
EXECUTEDSep 26, 2023Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5 →
EXECUTEDOct 5, 2022Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5 →
EXECUTEDAug 2, 2021Unregistered share sale disclosed (8-K item 3.02)8-K →

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full IMVT workspace